NewAmsterdam Pharma Co. NV (NAMS)
20.50
+0.97
(+4.97%)
USD |
NASDAQ |
Oct 27, 16:00
20.68
+0.18
(+0.88%)
After-Hours: 04:30
NewAmsterdam Pharma Enterprise Value : 1.777B for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 1.777B |
| October 26, 2026 | 1.663B |
| October 23, 2026 | 1.684B |
| October 22, 2026 | 1.904B |
| October 21, 2026 | 1.893B |
| October 20, 2026 | 1.894B |
| October 19, 2026 | 1.773B |
| October 16, 2026 | 1.698B |
| October 15, 2026 | 1.791B |
| October 14, 2026 | 1.719B |
| October 13, 2026 | 1.740B |
| October 12, 2026 | 1.865B |
| October 09, 2026 | 1.903B |
| October 08, 2026 | 1.866B |
| October 07, 2026 | 1.969B |
| October 06, 2026 | 1.985B |
| October 05, 2026 | 2.047B |
| October 02, 2026 | 2.094B |
| October 01, 2026 | 2.207B |
| September 30, 2026 | 2.226B |
| September 29, 2026 | 2.166B |
| September 28, 2026 | 2.139B |
| September 25, 2026 | 2.021B |
| September 24, 2026 | 2.040B |
| September 23, 2026 | 2.033B |
| Date | Value |
|---|---|
| September 22, 2026 | 2.109B |
| September 21, 2026 | 2.021B |
| September 18, 2026 | 2.011B |
| September 17, 2026 | 1.945B |
| September 16, 2026 | 1.857B |
| September 15, 2026 | 1.854B |
| September 14, 2026 | 1.996B |
| September 11, 2026 | 2.047B |
| September 10, 2026 | 1.937B |
| September 09, 2026 | 2.046B |
| September 08, 2026 | 2.380B |
| September 04, 2026 | 2.353B |
| September 03, 2026 | 2.406B |
| September 02, 2026 | 2.376B |
| September 01, 2026 | 2.297B |
| August 31, 2026 | 2.346B |
| August 28, 2026 | 2.412B |
| August 27, 2026 | 2.517B |
| August 26, 2026 | 2.589B |
| August 25, 2026 | 2.581B |
| August 24, 2026 | 2.524B |
| August 21, 2026 | 2.644B |
| August 20, 2026 | 2.633B |
| August 19, 2026 | 2.721B |
| August 18, 2026 | 2.571B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ProQR Therapeutics NV | 70.28M |
| Pharming Group NV | 808.61M |
| argenx SE | 54.54B |
| Alnylam Pharmaceuticals, Inc. | 30.01B |
| Ionis Pharmaceuticals, Inc. | 7.416B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -64.14M |
| Revenue (Quarterly) | 3.701M |
| Total Expenses (Quarterly) | 67.84M |
| EPS Diluted (Quarterly) | -0.5199 |
| Gross Profit Margin (Quarterly) | 98.41% |
| Profit Margin (Quarterly) | -1.73K% |
| Earnings Yield | -10.62% |
| Normalized Earnings Yield | -9.524 |